let's get to a big corporate story this morning, and that is around the drug companies than ovi, agreeingon deal -- the drug company sanofi, agreeing to buy princ ipai in a $3.4 billion deal. for more on this is our health reporter. good to see you. so what is sanofi picking up here? you.s, good morning to in this transaction, the latest force and no fee, they are getting this u.s. company, principia, as you say. they focus on treatments for multiple sclerosis and other disorders. now, this is a company that sanofi knows well. they are already partners in a drug that is under development for ms and other diseases, and we knew this was a possibility, actually. it was reported last month that they were considering potential acquisitions of u.s. targets, in thisem principia, so case, they are gaining access to drugs, inhibitors being developed to treat autoimmune disorders. the company sees a lot of promise in this field. key assets, if they put a pipeline in the product potential, in other words, individual drugs that could be rolled out for not just one illness but for multiple diseases, a